CNBX Pharmaceuticals Inc.
CNBX
$0.00
$0.000.00%
OTC PK
| 05/31/2025 | 02/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -37.56% | 75.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -37.56% | 75.82% | |||
| Operating Income | 37.56% | -75.82% | |||
| Income Before Tax | 14.47% | -102.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.47% | -102.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.47% | -102.91% | |||
| EBIT | 37.56% | -75.82% | |||
| EBITDA | 52.25% | -148.40% | |||
| EPS Basic | 36.36% | -100.00% | |||
| Normalized Basic EPS | 35.71% | -100.00% | |||
| EPS Diluted | 36.36% | -100.00% | |||
| Normalized Diluted EPS | 35.71% | -100.00% | |||
| Average Basic Shares Outstanding | 32.72% | 3.17% | |||
| Average Diluted Shares Outstanding | 32.72% | 3.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||